Although none of the biomarkers tested predicted response to sorafenib, patients with high s-c-KIT or low baseline hepatocyte growth factor concentration in the sorafenib cohort showed a trend towards enhanced benefit. 69 , 70 The ALICE-1 study looked at VEGF and VEGFR genotyping to predict outcomes with sorafenib and identified several polymorphisms (single nucleotide polymorphism [SNPs]) of VEGF that influenced PFS and OS. 71 The ALICE-2 study also showed SNPs of hypoxia-inducible factor-1α (HIF-1α) to be significant for PFS and OS.
← all excerpts
Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.
1
—
—